TNFRSF4 and neoplasm: Based upon the ability of IL-2 to strongly induce OX40 in vitro (Fig. 2), we sought to evaluate whether the provision of IL-2 in conjunction with anti-OX40 mAb therapy would augment anti-tumor immunity in vivo.